Page last updated: 2024-11-12

demeclocycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54680690
CHEMBL ID1591
CHEBI ID4392
SCHEMBL ID3252
SCHEMBL ID516084
SCHEMBL ID13169106
SCHEMBL ID17710674
SCHEMBL ID23723072
MeSH IDM0005801

Synonyms (109)

Synonym
DIVK1C_000863
KBIO1_000863
(4s,4as,5as,6s,12as)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
D03680
demethylchlortetracycline (jan)
demeclocycline (usp)
127-33-3
7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide
demeclocyclinum [inn-latin]
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4s,4as,5as,6s,12as)-
demethylchlortetracyclinum
6-demetil-7-clorotetraciclina [italian]
6-demethylchlorotetracycline
hsdb 3051
demeclociclina [inn-spanish]
ledermycin
tri-demethylchlortetracycline
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4s-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-
demeclocycline [usan:ban]
demethylchlorotetracycline
6-demethylchlortetracycline
einecs 204-834-8
SPECTRUM_000896
SMP1_000091
BPBIO1_000844
BSPBIO_000766
PRESTWICK3_000753
SPECTRUM5_000831
IDI1_000863
LOPAC0_000421
PRESTWICK2_000753
(4s,4as,5as,6s,12as)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
demeclocycline
7-chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
dmct
demethylchlortetracyclin
demethylchlortetracycline
6-demethyl-7-chlorotetracycline
7-chloro-6-demethyltetracycline
[4s-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide
DB00618
dmctc
KBIOSS_001376
KBIOGR_000926
KBIO2_003944
KBIO2_001376
KBIO2_006512
KBIO3_001355
NINDS_000863
SPBIO_002705
SPECTRUM3_000378
SPECTRUM2_001132
PRESTWICK1_000753
SPECTRUM4_000313
PRESTWICK0_000753
SPBIO_001023
BSPBIO_002135
NCGC00162149-02
NCGC00162149-03
NCGC00162149-04
demeclocyclinum
CHEBI:4392 ,
demeclociclina
CHEMBL1591
unii-5r5w9ici6o
demeclocycline [usp:inn:ban]
5r5w9ici6o ,
CCG-204513
6-demetil-7-clorotetraciclina
methylchlorotetracycline
demeclocycline [vandf]
demeclocycline [who-dd]
demeclocycline [hsdb]
chlortetracycline hydrochloride impurity b [ep impurity]
demeclocycline [mart.]
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-
demethylchlortetracycline [jan]
demeclocycline [usp monograph]
demeclocycline [mi]
demeclocycline [inn]
FMTDIUIBLCQGJB-SEYHBJAFSA-N
SCHEMBL3252
SCHEMBL516084
1,3,5-benzenetrisulfonylchloride
SCHEMBL13169106
AB00053449_04
DTXSID1022893 ,
J-005483
SCHEMBL17710674
HY-121268
sr-01000000066
SR-01000000066-4
SBI-0050406.P004
rkl10089
NCGC00162149-10
(4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
GUXHBMASAHGULD-SEYHBJAFSA-N
NCGC00162149-06
SDCCGSBI-0050406.P005
NCGC00162149-14
gtpl10905
Q2736402
127-33-3 (free base)
SCHEMBL23723072
EN300-37299894
CS-0081339
1165453-98-4
(4s,4as,5as,6s,12as)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-1,2,3,4,4a,5,5a,6,12,12a-decahydrotetracene-1,3,12-trione
AKOS040740988

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Up to this time, amoxicillin has not been commercially available as an injectable dosage form."( Pneumococcal meningitis-therapeutic studies in mice.
Hirth, RS; Price, KE; Tsai, YH; Williams, EB, 1975
)
0.25
" It is concluded that doxycycline is the most potent photosensitizer at the dosage tested."( Double blind cross-over studies on phototoxicity to three tetracycline derivatives in human volunteers.
Bjellerup, M; Ljunggren, B, 1987
)
0.27
" No evidence was found for toxicity of tetracycline or its analogues for the dosage given."( Effect of intrauterine administration of tetracyclines on cynomolgus monkeys.
Dubin, NH; Ghodgaonkar, RB; King, TM; Parmley, TH; Rosenshein, NB; Strandberg, JD, 1984
)
0.27
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Demeclocycline Action Pathway14

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency25.92900.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency23.47950.100020.879379.4328AID488773; AID588453
GLS proteinHomo sapiens (human)Potency3.16230.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency0.66950.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency6.01201.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.51930.035520.977089.1251AID504332
hexokinase-4 isoform 1Homo sapiens (human)Potency12.58932.511913.800328.1838AID743207
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
glucokinase regulatory proteinHomo sapiens (human)Potency12.58932.511913.800328.1838AID743207
flap endonuclease 1Homo sapiens (human)Potency29.93490.133725.412989.1251AID488816; AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.93300.425612.059128.1838AID504536
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
M-phase phosphoprotein 8Homo sapiens (human)Potency29.93490.177824.735279.4328AID488949
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID562241Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID562242Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID562243Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID562244Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540235Phospholipidosis-negative literature compound
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1055951Antibacterial activity against Acinetobacter baumannii ATCC BAA-747 after 16 hrs2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID562245Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID562240Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1566490Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (797)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990644 (80.80)18.7374
1990's48 (6.02)18.2507
2000's41 (5.14)29.6817
2010's53 (6.65)24.3611
2020's11 (1.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (7.24%)5.53%
Reviews45 (5.09%)6.00%
Case Studies85 (9.62%)4.05%
Observational0 (0.00%)0.25%
Other690 (78.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307) [NCT00873808]0 participants (Actual)Observational2008-10-31Withdrawn(stopped due to lack of accrual)
Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors [NCT02740933]Phase 140 participants (Anticipated)Interventional2016-04-30Not yet recruiting
Bone Histomorphometry of the Proximal Femur in Denosumab-treated Subjects Undergoing Total Hip Replacement [NCT02576652]Phase 46 participants (Actual)Interventional2015-12-22Completed
Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis [NCT01753856]Phase 469 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01753856 (23) [back to overview]Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the CC of the Iliac Crest
NCT01753856 (23) [back to overview]Activation Frequency (Ac.f) in the CC, EC and IC of the Iliac Crest
NCT01753856 (23) [back to overview]Adjusted Apposition Rate (Aj.AR) in the CC, EC and IC of the Iliac Crest
NCT01753856 (23) [back to overview]Average Length of DLs in the CC, EC, IC and PC of the Iliac Crest
NCT01753856 (23) [back to overview]Change From Baseline to 3 Months in Bone Formation Rate/Bone Surface (BFR/BS ) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Change From Baseline to 3 Months in Label Length Within Each Basic Multicellular Unit (BMU) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Change From Baseline to 3 Months in Mineral Apposition Rate (MAR) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Change From Baseline to 3 Months in MS/BS in the Endocortical Compartment (EC), Intracortical Compartment (IC), and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]MS/BS in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies 3 Months Post First Dose of Study Drug
NCT01753856 (23) [back to overview]Number of Samples With Single or Double Tetracycline Labels, SL and DL, or No Tetracycline Labels in the CC, Endocortical Compartment (EC), Intracortical Compartment (IC) and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Osteoid Thickness (O.Th) in the CC, EC and IC of the Iliac Crest
NCT01753856 (23) [back to overview]Percentage Change From Baseline to 1, 3, and 6 Months in Intact Parathyroid Hormone (PTH)
NCT01753856 (23) [back to overview]Percentage Change From Baseline to 1, 3, and 6 Months in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX)
NCT01753856 (23) [back to overview]Percentage Change From Baseline to 1, 3, and 6 Months in Serum Osteocalcin
NCT01753856 (23) [back to overview]Percentage Change From Baseline to 1, 3, and 6 Months in Serum Procollagen Type I N-terminal Propeptide (P1NP)
NCT01753856 (23) [back to overview]Percentage of Bone With Remodeling-Based and Modeling-Based Formations in the CC, EC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Percentage of Eroded Surface/Bone Surface (ES/BS) in the CC, EC and IC of the Iliac Crest
NCT01753856 (23) [back to overview]Percentage of Mineralizing Surface With Remodeling-Based Formation and Modeling-Based Formation in the CC, EC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the CC, EC and IC of the Iliac Crest
NCT01753856 (23) [back to overview]Percentage of Overfilled Remodeling Sites in the CC, EC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Percentage of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS or dLS/BS) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies
NCT01753856 (23) [back to overview]Wall Thickness (W.Th) in the CC, EC and IC of the Iliac Crest
NCT02576652 (4) [back to overview]Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck
NCT02576652 (4) [back to overview]Modeling Based Formation Units in the Femoral Neck
NCT02576652 (4) [back to overview]Overfilled Remodeling-based Formation Units in the Femoral Neck
NCT02576652 (4) [back to overview]Remodeling-based Formation Units Including Overfilled Units in the Femoral Neck

Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies

MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling, and calculated as the sum of the total extent of double label (DL) plus half the extent of single label (SL) divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or no label (NL) suggested varying degrees of suppression of bone formation. (NCT01753856)
Timeframe: Baseline, 3 months post first dose of study drug

Interventionpercentage of BS (Median)
Teriparatide12.43
Denosumab-2.51

[back to top]

Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the CC of the Iliac Crest

OV is the percentage of a given volume of bone tissue that consists of new unmineralized bone matrix (osteoid). Percentage = (OV/BV) *100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

Interventionpercentage of BV (Median)
Teriparatide2.58
Denosumab0.39

[back to top]

Activation Frequency (Ac.f) in the CC, EC and IC of the Iliac Crest

Ac.f is the probability of new remodeling cycles initiated on the BS per year. Ac.f = (BFR/BS) / wall thickness. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 µm/day or counted as missing. NL cases were assigned a value of zero. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionnew cycles per year (Median)
DL Only, in CC (n=31, 26)DL and Imputed SL, in CC (n=31, 35)DL Only, in EC (n=30, 29)DL and Imputed SL, in EC (n=30, 35)DL Only, in IC (n=30, 25)DL and Imputed SL, in IC (n=30, 35)
Denosumab0.100.060.350.340.170.12
Teriparatide1.411.412.772.771.881.88

[back to top]

Adjusted Apposition Rate (Aj.AR) in the CC, EC and IC of the Iliac Crest

Aj.AR is MAR averaged over the entire osteoid surface and in a steady state is an estimate of the mean rate of matrix apposition. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested suppression of bone formation. BFR = MAR * (MS/BS). SL cases were imputed to a value of 0.3 µm/day or counted as missing. NL cases were counted as missing. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionµm/day (Median)
DL Only, in CC (n=31, 24)DL and Imputed SL, in CC (n=31, 33)DL Only, in EC (n=30, 25)DL and Imputed SL, in EC (n=30, 30)DL Only, in IC (n=30, 24)DL and Imputed SL, in IC (n=30, 33)
Denosumab0.210.140.650.580.580.35
Teriparatide0.580.580.760.761.031.03

[back to top]

Average Length of DLs in the CC, EC, IC and PC of the Iliac Crest

The length of TET DLs is a measure of the extent of bone formation in each compartment within individual remodeling units and is measured in mm. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionmm (Mean)
DL, in CC (n=31, 24)DL, in EC (n=30, 25)DL, in IC (n=30, 24)DL, in PC (n=10, 1)
Denosumab0.310.350.270.32
Teriparatide0.400.480.430.38

[back to top]

Change From Baseline to 3 Months in Bone Formation Rate/Bone Surface (BFR/BS ) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies

BFR/BS is the volume of mineralized bone formed per unit surface of bone per unit of time [mm cubed per mm squared per year (mm³/mm²/year)]. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicates active bone formation, a SL or NL suggests suppression of bone formation. BFR = MAR * (MS/BS). SL cases were imputed to a value of 0.3 mcm/day or counted as missing. NL cases were assigned a value of zero. (NCT01753856)
Timeframe: Baseline, 3 months post first dose of study drug

,
Interventionmm³/mm²/year (Median)
DL Only, in CC (n=30, 26)DL and Imputed SL, in CC (n=31, 35)DL Only, in EC (n=29, 28)DL and Imputed SL, in EC (n=30, 35)DL Only, in IC (n=30, 25)DL and Imputed SL, in IC (n=30, 35)DL Only, in PC (n=6, 16)DL and Imputed SL, in PC (n=30, 35)
Denosumab-0.0056-0.0055-0.0069-0.0069-0.0184-0.01840.0000-0.0005
Teriparatide0.02800.02750.05090.05010.04550.04550.02310.0015

[back to top]

Change From Baseline to 3 Months in Label Length Within Each Basic Multicellular Unit (BMU) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies

BMUs are local groups of osteoblasts and osteoclasts that act in concert to complete a single remodeling cycle. The label length is a measure of the extent of the mineralization front within each BMU in the CC, EC, IC and PC. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation, and a SL or NL suggested suppression of bone formation. (NCT01753856)
Timeframe: Baseline, 3 months post first dose of study drug

,
Interventionmillimeters (mm) (Median)
CC (n=30, 24)EC (n=28, 25)IC (n=30, 24)PC (n=4, 1)
Denosumab0.050.030.020.10
Teriparatide0.190.250.180.12

[back to top]

Change From Baseline to 3 Months in Mineral Apposition Rate (MAR) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies

MAR is a measure of the linear rate of production of mineralized bone matrix by osteoblasts and is measured by the mean distance between 2 consecutive labels divided by the time interval. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation, and a SL or NL suggested suppression of bone formation. SL cases were imputed to a value of 0.3 micrometers per day (µm/day) or counted as missing. NL cases were reported as missing. (NCT01753856)
Timeframe: Baseline, 3 months post first dose of study drug

,
Interventionmcm/day (Median)
DL Only, in CC (n=30, 24)DL and Imputed SL, in CC (n=31, 33)DL Only, in EC (n=28, 25)DL and Imputed SL, in EC (n=29, 31)DL Only, in IC (n=30, 24)DL and Imputed SL, in IC (n=30, 34)DL Only, in PC (n=4, 1)DL and Imputed SL, in PC (n=19, 4)
Denosumab-0.04-0.06-0.07-0.09-0.18-0.22-0.04-0.04
Teriparatide0.000.010.030.030.200.200.050.00

[back to top]

Change From Baseline to 3 Months in MS/BS in the Endocortical Compartment (EC), Intracortical Compartment (IC), and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies

MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling and is calculated as the sum of the total extent of DL plus half the extent of SL divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested varying degrees of suppression of bone formation. (NCT01753856)
Timeframe: Baseline, 3 months post first dose of study drug

,
Interventionpercentage of BS (Median)
ECICPC
Denosumab-2.97-6.70-0.39
Teriparatide26.129.392.40

[back to top]

MS/BS in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies 3 Months Post First Dose of Study Drug

MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling and is calculated as the sum of the total extent of DL plus half the extent of SL divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested varying degrees of suppression of bone formation. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of BS (Median)
CC (n=31, 35)EC (n=30, 35)IC (n=30, 35)PC (n=30, 35)
Denosumab0.965.423.050.00
Teriparatide18.7339.5021.694.69

[back to top]

Number of Samples With Single or Double Tetracycline Labels, SL and DL, or No Tetracycline Labels in the CC, Endocortical Compartment (EC), Intracortical Compartment (IC) and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies

(NCT01753856)
Timeframe: 3 months post first dose of study drug

,
InterventionSamples (Number)
DL and SL, in CC (n=31, 35)DL Only, in CC (n=31, 35)SL Only, in CC (n=31, 35)No Label, in CC (n=31, 35)DL and SL, in EC (n=30, 35)DL Only, in EC (n=30, 35)SL Only, in EC (n=30, 35)No Label, in EC (n=30, 35)DL and SL, in IC (n=30, 35)DL Only, in IC (n=30, 35)SL Only, in IC (n=30, 35)No Label, in IC (n=30, 35)DL and SL, in PC (n=30, 35)DL Only, in PC (n=30, 35)SL Only, in PC (n=30, 35)No Label, in PC (n=30, 35)
Denosumab240922506424010110430
Teriparatide310003000030000100191

[back to top]

Osteoid Thickness (O.Th) in the CC, EC and IC of the Iliac Crest

O.Th is a measure of the average thickness of osteoid seams. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionmicrometers (mcm) (Median)
CC (n= 31, 35)EC (n= 30, 35)IC (n= 30, 35)
Denosumab3.784.334.68
Teriparatide6.126.997.08

[back to top]

Percentage Change From Baseline to 1, 3, and 6 Months in Intact Parathyroid Hormone (PTH)

PTH regulates calcium and phosphate metabolism in bone and kidney, and is typically measured in serum using the intact PTH assay. Percentage = (PTH value at specified time points - PTH value at baseline) / PTH value at baseline * 100. (NCT01753856)
Timeframe: Baseline, 1, 3, and 6 months post first dose of study drug

,
Interventionpercentage change in PTH (Median)
1 month (n=28, 34)3 months (n=18, 28)6 months (n=27, 33)
Denosumab72.2446.6830.40
Teriparatide-26.89-32.16-40.18

[back to top]

Percentage Change From Baseline to 1, 3, and 6 Months in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX)

CTX is a marker of bone turnover and is a measure of bone resorption. Percentage = (CTX value at specified time points - CTX value at baseline) / (CTX value at baseline) * 100. (NCT01753856)
Timeframe: Baseline, 1, 3, and 6 months post first dose of study drug

,
Interventionpercentage change in CTX (Median)
1 month (n=31, 33)3 months (n=21, 29)6 months (n=29, 33)
Denosumab-90.70-90.77-82.50
Teriparatide6.0973.0489.13

[back to top]

Percentage Change From Baseline to 1, 3, and 6 Months in Serum Osteocalcin

Osteocalcin is a marker of bone turnover and a measure of osteoblast function. Percentage = (osteocalcin value at specified time points - osteocalcin value at baseline) / (osteocalcin value at baseline) * 100. (NCT01753856)
Timeframe: Baseline, 1, 3, and 6 months post first dose of study drug

,
Interventionpercentage change in osteocalcin (Median)
1 month (n=31, 33)3 months (n=20, 29)6 months (n=29, 31)
Denosumab-6.56-45.70-50.53
Teriparatide90.53123.66187.29

[back to top]

Percentage Change From Baseline to 1, 3, and 6 Months in Serum Procollagen Type I N-terminal Propeptide (P1NP)

P1NP is a marker of bone turnover and is a measure of bone formation. Percentage = (P1NP value at specified time points - P1NP value at baseline) / P1NP value at baseline * 100. (NCT01753856)
Timeframe: Baseline, 1, 3, and 6 months post first dose of study drug

,
Interventionpercentage change in P1NP (Median)
1 month (n=33, 34)3 months (n=22, 29)6 months (n=31, 32)
Denosumab-11.56-66.64-68.24
Teriparatide134.38213.15284.22

[back to top]

Percentage of Bone With Remodeling-Based and Modeling-Based Formations in the CC, EC and PC of the Iliac Crest Bone Biopsies

In this study, post-treatment DLs in the CC, EC, and PC were classified as remodeling-based or modeling-based bone formations which was determined by whether the underlying reversal line was scalloped or smooth and by the collagen fiber orientation. Percentage = (remodeling-based formation units or modeling-based formation units/ total bone formation units) * 100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of the total formation unit (Median)
Remodeling-Based Bone Formation in CC (n=31, 32)Modeling-Based Bone Formation in CC (n=31, 32)Remodeling-Based Bone Formation in EC (n=30, 29)Modeling-Based Bone Formation in EC (n=30, 29)Remodeling-Based Bone Formation in PC (n=29, 5)Modeling-Based Bone Formation in PC (n=29, 5)
Denosumab90.839.17100.000.000.00100.00
Teriparatide89.0210.9883.3316.670.00100.0

[back to top]

Percentage of Eroded Surface/Bone Surface (ES/BS) in the CC, EC and IC of the Iliac Crest

ES/BS is the fraction of the entire trabecular surface occupied by resorption bays, including both those with and without osteoclasts. It is an indicator of bone resorption. Percentage = (ES/BS) *100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of BS (Median)
CC (n=31, 35)EC (n=30, 35)IC (n=30, 35)
Denosumab1.521.651.27
Teriparatide3.733.7911.19

[back to top]

Percentage of Mineralizing Surface With Remodeling-Based Formation and Modeling-Based Formation in the CC, EC and PC of the Iliac Crest Bone Biopsies

"The percentage of mineralizing surface where post-treatment DLs in the CC, EC, and PC were classified as remodeling-based or modeling based bone formation based on collagen fiber orientation and whether the underlying reversal line was scalloped or smooth.~Percentage = percentage remodeling- or modeling-based formation units * MS/BS" (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of the total formation unit (Median)
Remodeling-Based Bone Formation in CC (n=31, 35)Modeling-Based Bone Formation in CC (n=31, 35)Remodeling-Based Bone Formation in EC (n=30, 35)Modeling-Based Bone Formation in EC (n=30, 35)Remodeling-Based Bone Formation in PC (n=30, 35)Modeling-Based Bone Formation in PC (n=30, 35)
Denosumab0.870.095.420.000.000.00
Teriparatide16.672.0632.926.580.004.69

[back to top]

Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the CC, EC and IC of the Iliac Crest

OS is the percentage of the entire trabecular BS that is covered by osteoid. Percentage = (OS / BS) *100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of BS (Median)
CC (n=31, 35)EC (n=30, 35)IC (n=30, 35)
Denosumab3.466.954.34
Teriparatide20.5130.8517.81

[back to top]

Percentage of Overfilled Remodeling Sites in the CC, EC and PC of the Iliac Crest Bone Biopsies

The percentage of overfilled remodeling sites in the CC, EC, and PC were defined as the percentage of observed remodeling units in which the second DL (TET) extended beyond the limits of the scalloped reversal line and into the adjacent, previously unresorbed surface of the bone. Percentage = (overfilled remodeling bone formation unit / total bone formation unit) * 100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of overfilled remodeling site (Median)
CC (n=31, 32)EC (n=30, 29)PC (n=29, 5)
Denosumab0.000.000.00
Teriparatide17.7421.980.00

[back to top]

Percentage of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS or dLS/BS) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies

At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested suppression of bone formation. Percentage = (Single or double TET labels / BS) *100. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionpercentage of TET label (Median)
sLS/BS, in CC (n=31, 35)dLS/BS, in CC (n=31, 35)sLS/BS, in EC (n=30, 35)dLS/BS, in EC (n=30, 35)sLS/BS, in IC (n=30, 35)dLS/BS, in IC (n=30, 35)sLS/BS, in PC (n=30, 35)dLS/BS, in PC (n=30, 35)
Denosumab1.280.227.181.684.660.830.000.00
Teriparatide15.4410.4424.2428.8415.2814.969.370.00

[back to top]

Wall Thickness (W.Th) in the CC, EC and IC of the Iliac Crest

W.Th is the distance from the cement line to the marrow space of completed trabecular bone packets. (NCT01753856)
Timeframe: 3 months post first dose of study drug

,
Interventionµm (Median)
CC (n=31, 35)EC (n=30, 35)IC (n=30, 35)
Denosumab24.0330.0837.80
Teriparatide26.2931.8838.25

[back to top]

Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck

"Femoral neck bone samples were prepared according to standard procedures for bone histology and bone histomorphometry at a central bone histomorphometry facility.~Modeling based formation units in active bone-forming, tetracycline-labeled surfaces were identified by a smooth cement line.~The percentage of participants with fluorochrome labeling present in the cancellous or periosteal, or endocortical surfaces of the femoral neck indicative of modeling-based bone formation is reported." (NCT02576652)
Timeframe: Days 22-58 (at the time of hip replacement surgery)

Interventionpercentage of participants (Number)
Osteoarthritis Participants100

[back to top]

Modeling Based Formation Units in the Femoral Neck

"Femoral neck bone samples were prepared according to standard procedures for bone histology and bone histomorphometry at a central bone histomorphometry facility.~Modeling based formation units in active bone-forming, tetracycline-labeled surfaces were identified by a smooth cement line. The number of modeling based formation units was evaluated at the cancellous, periosteal, and endocortical regions and is reported in units per mm of bone surface." (NCT02576652)
Timeframe: Days 22-58 (at the time of hip replacement surgery)

Interventionunits/mm (Mean)
Cancellous RegionEndocortical RegionPeriosteal Region
Osteoarthritis Participants0.14550.22230.1990

[back to top]

Overfilled Remodeling-based Formation Units in the Femoral Neck

"Femoral neck bone samples were prepared according to standard procedures for bone histology and bone histomorphometry at a central bone histomorphometry facility.~Remodeling-based formation units in active bone-forming, tetracycline-labeled surfaces were identified by a scalloped cement line. The number of overfilled remodeling-based formation units was evaluated at the cancellous, periosteal, and endocortical regions and is reported as units per mm of bone surface." (NCT02576652)
Timeframe: Days 22-58 (at the time of hip replacement surgery)

Interventionunits/mm (Mean)
Cancellous RegionEndocortical RegionPeriosteal Region
Osteoarthritis Participants0.00380.01080.0000

[back to top]

Remodeling-based Formation Units Including Overfilled Units in the Femoral Neck

"Femoral neck bone samples were prepared according to standard procedures for bone histology and bone histomorphometry at a central bone histomorphometry facility.~Remodeling based formation units in active bone-forming, tetracycline-labeled surfaces were identified by a scalloped cement line. The number of remodeling based formation units including overfilled units was evaluated at the cancellous, periosteal, and endocortical regions and is reported in units per mm of bone surface." (NCT02576652)
Timeframe: Days 22-58 (at the time of hip replacement surgery)

Interventionunits/mm (Mean)
Cancellous RegionEndocortical RegionPeriosteal Region
Osteoarthritis Participants0.02850.03230.0033

[back to top]